Corindus Vascular Robotics, Inc. (NYSE:CVRS) is on recovery track with 208.69% gain from a 1-year low price of $0.41. The company lost -8.82% to attain the price of $1.24 on 10/16/2017. Throughout the recent session, the prices were hovering between $1.16 and $1.35. These shares are 121.77% off its target price of $2.75 and the current market capitalization stands at $244.17M. The recent change has given its price a -22.04% deficit over SMA 50 and -44.89% deficit over its 52-week high. The stock witnessed -21.52% declines, -26.63% declines and 5.08% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CVRS’s volatility during a week at 7.59% and during a month it has been found around 5.87%.Corindus Vascular Robotics, Inc. (CVRS) Top Holders
Institutional investors currently hold around $90 million or 53.9% in CVRS stock. Look at its top three institutional owners. Healthcor Management, L.P. owns $27.18 million in Corindus Vascular Robotics, Inc., which represents roughly 11.13% of the company’s market cap and approximately 30.19% of the institutional ownership. Similar statistics are true for the second largest owner, Consonance Capital Management Lp, which owns 15,114,872 shares of the stock are valued at $20.56 million. The third largest holder is Hudson Executive Capital Lp, which currently holds $15.42 million worth of this stock and that ownership represents nearly 6.31% of its market capitalization.
At the end of June reporting period, 36 institutional holders increased their position in Corindus Vascular Robotics, Inc. (NYSE:CVRS) by some 4,233,992 shares, 15 decreased positions by 2,105,026 and 9 held positions by 59,574,076. That puts total institutional holdings at 65,913,094 shares, according to SEC filings. The stock grabbed 10 new institutional investments totaling 157,370 shares while 6 institutional investors sold out their entire positions totaling 973,710 shares.Corindus Vascular Robotics, Inc. (NYSE:CVRS) Insider Trades
Multiple company employees have indulged in significant insider trading. Corindus Vascular Robotics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Koninklijke Philips Nv has sold 3,334,586 shares of Corindus Vascular Robotics, Inc. (CVRS) in trading session dated Oct. 11, 2017. These shares are worth $5,001,879 and were traded at $1.5 each. The SEC filing shows that Cannon Louis A performed a purchase of 27,000 shares. The Director added these shares by way of transaction on Mar. 22, 2017. The company’s shares were assimilated at $1.3 per share worth to an investment of some $35,100 on account of Cannon Louis A.
10% Owner, Koninklijke Philips Nv, purchased 7,557,436 common shares of Corindus Vascular Robotics, Inc. (CVRS) in the open market. In a transaction dated Feb. 28, 2017, the shares were bought at an average price of $0.66, giving away a sum of $4,987,908. After this purchase, 24,965,253 common shares of CVRS are directly owned by the insider, with total stake valued at $30,956,914.
In the transaction dated Feb. 28, 2017, the great number of shares acquired came courtesy the Director, 10% Owner; Lightcap Jeffrey C added a total of 7,557,436 shares at an average price of $0.66, amounting to approximately $4,987,908. The insider now directly owns 32,500,478 shares worth $40,300,593.Corindus Vascular Robotics, Inc. (CVRS) Analyst Guide
Not many analysts have released their opinion on Corindus Vascular Robotics, Inc. (NYSE:CVRS), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.